Kodiak Sciences
Clinical trials sponsored by Kodiak Sciences, explained in plain language.
Ophthalmology biotech focused on retinal disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug aims to restore vision in inflammatory swelling Results expected Feb 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
- New eye drug aims to restore vision in Inflammation-Related swelling Results expected Apr 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
Can a new eye injection beat the current standard for diabetic vision loss?
Disease control Recruiting nowThis phase 3 trial compares an experimental drug, tabirafusp tedromer, against the standard treatment aflibercept for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 910 adults with DME will receive injections into the eye and be follow…
Phase 3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eye drug aims to restore vision in Inflammation-Related swelling
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called tabirafusp alfa (KSI-101) given as an eye injection for people with macular edema (swelling) caused by inflammation. The study will compare the drug to a sham (fake) injection in 600 participants to see if it improves vision an…
Phase 3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New eye drug aims to restore vision in inflammatory swelling
Disease control Recruiting nowThis study tests an experimental drug called tabirafusp alfa (KSI-101) given as an eye injection to treat macular edema (swelling in the back of the eye) caused by inflammation. About 300 adults with vision loss from this condition will receive either the drug or a sham injection…
Phase 3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC